Thromboxane Inhibitors Attenuate Inflammatory and Fibrotic Changes in Rat Liver Despite Continued Ethanol Administrations

Alcoholism: Clinical and Experimental Research

Volumn 37, Issue 1, 2013, Pages 31-39

  Nanji, Amin A ^a   Liong, Emily C ^b   Xiao, Jia ^b   Tipoe, George L ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Alcoholic liver disease; Fibrosis; Inflammation; NF B; Thromboxane inhibitor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; CYCLOOXYGENASE 2; ENDOTOXIN; FISH OIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; THROMBOXANE; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; THROMBOXANE RECEPTOR BLOCKING AGENT; THROMBOXANE SYNTHASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ALCOHOL BLOOD LEVEL; ALCOHOL LIVER CIRRHOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DISEASE SEVERITY; FATTY LIVER; FLUID THERAPY; HEPATITIS; HISTOPATHOLOGY; LIPID PEROXIDATION; LIVER FIBROSIS; LIVER NECROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CYCLOOXYGENASE 2; ENDOTOXINS; ETHANOL; FATTY LIVER, ALCOHOLIC; FIBROSIS; LIPID PEROXIDATION; LIVER; MALE; NF-KAPPA B; OXAZOLES; PYRIDINES; RATS; RATS, WISTAR; RECEPTORS, THROMBOXANE; RNA, MESSENGER; THROMBOXANE-A SYNTHASE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

RATTUS;

EID: 84871999081     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2012.01838.x     Document Type: Article

References (38)

1. Ambler J, Butler KD, Ku EC, Maguire ED, Smith JR, Wallis RB (1985) CGS 12970: a novel, long acting thromboxane synthetase inhibitor. Br J Pharmacol 86:497-504.
2. Baeuerle PA (1998) IkappaB-NF-kappaB structures: at the interface of inflammation control. Cell 95:729-731.
3. Beier JI, McClain CJ (2010) Mechanisms and cell signaling in alcoholic liver disease. Biol Chem 391:1249-1264.
4. Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37:911-917.
5. Cao Q, Mak KM, Lieber CS (2002) DLPC decreases TGF-beta1-induced collagen mRNA by inhibiting p38 MAPK in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 283:G1051-G1061.
6. Comporti M, Arezzini B, Signorini C, Vecchio D, Gardi C (2009) Oxidative stress, isoprostanes and hepatic fibrosis. Histol Histopathol 24:893-900.
7. Cunningham CC, Bailey SM (2001) Ethanol consumption and liver mitochondria function. Biol Signals Recept 10:271-282.
8. Gobejishvili L, Barve S, Joshi-Barve S, Uriarte S, Song Z, McClain C (2006) Chronic ethanol-mediated decrease in cAMP primes macrophages to enhanced LPS-inducible NF-kappaB activity and TNF expression: relevance to alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 291:G681-G688.
9. Kato J, Sato Y, Inui N, Nakano Y, Takimoto R, Takada K, Kobune M, Kuroiwa G, Miyake S, Kohgo Y, Niitsu Y (2003) Ethanol induces transforming growth factor-alpha expression in hepatocytes, leading to stimulation of collagen synthesis by hepatic stellate cells. Alcohol Clin Exp Res 27:58S-63S.
10. Kohan DE (1992) Eicosanoids: potential regulators of extracellular matrix formation in the kidney. J Lab Clin Med 120:4-6.
11. Lieber CS (2004) Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis. Alcohol 34:9-19.
12. Liu SL, Degli Esposti S, Yao T, Diehl AM, Zern MA (1995) Vitamin E therapy of acute CCl4-induced hepatic injury in mice is associated with inhibition of nuclear factor kappa B binding. Hepatology 22:1474-1481.
13. Mandrekar P, Szabo G (2009) Signalling pathways in alcohol-induced liver inflammation. J Hepatol 50:1258-1266.
14. Mann RE, Smart RG, Govoni R (2003) The epidemiology of alcoholic liver disease. Alcohol Res Health 27:209-219.
15. McVicker BL, Tuma DJ, Casey CA (2007) Effect of ethanol on pro-apoptotic mechanisms in polarized hepatic cells. World J Gastroenterol 13:4960-4966.
16. Meagher EA, Barry OP, Burke A, Lucey MR, Lawson JA, Rokach J, FitzGerald GA (1999) Alcohol-induced generation of lipid peroxidation products in humans. J Clin Invest 104:805-813.
17. Morimoto M, Hagbjork AL, Wan YJ, Fu PC, Clot P, Albano E, Ingelman-Sundberg M, French SW (1995) Modulation of experimental alcohol-induced liver disease by cytochrome P450 2E1 inhibitors. Hepatology 21:1610-1617.
18. Morrow JD (2006) The isoprostanes-unique products of arachidonate peroxidation: their role as mediators of oxidant stress. Curr Pharm Des 12:895-902.
19. Nanji AA, Jokelainen K, Rahemtulla A, Miao L, Fogt F, Matsumoto H, Tahan SR, Su GL (1999) Activation of nuclear factor kappa B and cytokine imbalance in experimental alcoholic liver disease in the rat. Hepatology 30:934-943.
20. Nanji AA, Khwaja S, Rahemtulla A, Miao L, Zhao S, Tahan SR (1997a) Thromboxane inhibitors attenuate pathological changes in alcoholic liver disease in the rat. Gastroenterology 112:200-207.
21. Nanji AA, Khwaja S, Tahan SR, Sadrzadeh SM (1994) Plasma levels of a novel noncyclooxygenase-derived prostanoid (8-isoprostane) correlate with severity of liver injury in experimental alcoholic liver disease. J Pharmacol Exp Ther 269:1280-1285.
22. Nanji AA, Rahemtulla A, Daly T, Khwaja S, Miao L, Zhao S, Tahan SR (1997b) Cholesterol supplementation prevents necrosis and inflammation but enhances fibrosis in alcoholic liver disease in the rat. Hepatology 26:90-97.
23. Negrete H, Studer RK, Craven PA, DeRubertis FR (1995) Role for transforming growth factor beta in thromboxane-induced increases in mesangial cell fibronectin synthesis. Diabetes 44:335-339.
24. Nourooz-Zadeh J, Halliwell B, Anggard EE (1997) Evidence for the formation of F3-isoprostanes during peroxidation of eicosapentaenoic acid. Biochem Biophys Res Commun 236:467-472.
25. Ogletree ML, Harris DN, Schumacher WA, Webb ML, Misra RN (1993) Pharmacological profile of BMS 180, 291: a potent, long-acting, orally active thromboxane A2/prostaglandin endoperoxide receptor antagonist. J Pharmacol Exp Ther 264:570-578.
26. Pratico D, Lawson JA, Rokach J, FitzGerald GA (2001) The isoprostanes in biology and medicine. Trends Endocrinol Metab 12:243-247.
27. Recknagel RO, Glende EA Jr (1984) Spectrophotometric detection of lipid conjugated dienes. Methods Enzymol 105:331-337.
28. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J (2009) Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 373:2223-2233.
29. Reinke LA, Moore DR, Nanji AA (2000) Pronounced hepatic free radical formation precedes pathological liver injury in ethanol-fed rats. Alcohol Clin Exp Res 24:332-335.
30. Roberts LJ 2nd, Montine TJ, Markesbery WR, Tapper AR, Hardy P, Chemtob S, Dettbarn WD, Morrow JD (1998) Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 273:13605-13612.
31. Rosenfeld L, Grover GJ, Stier CT Jr (2001) Ifetroban sodium: an effective TxA2/PGH2 receptor antagonist. Cardiovasc Drug Rev 19:97-115.
32. Schmid RM, Adler G (2000) NF-kappaB/rel/IkappaB: implications in gastrointestinal diseases. Gastroenterology 118:1208-1228.
33. Smith WL, Langenbach R (2001) Why there are two cyclooxygenase isozymes. J Clin Invest 107:1491-1495.
34. Tacke F, Luedde T, Trautwein C (2009) Inflammatory pathways in liver homeostasis and liver injury. Clin Rev Allergy Immunol 36:4-12.
35. Thurman RG (1998) II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. Am J Physiol 275:G605-G611.
36. Tsukamoto H (1999) Cytokine regulation of hepatic stellate cells in liver fibrosis. Alcohol Clin Exp Res 23:911-916.
37. Tsukamoto H, Towner SJ, Ciofalo LM, French SW (1986) Ethanol-induced liver fibrosis in rats fed high fat diet. Hepatology 6:814-822.
38. Yokoyama Y, Nimura Y, Nagino M, Bland KI, Chaudry IH (2005) Role of thromboxane in producing hepatic injury during hepatic stress. Arch Surg 140:801-807.